Voya Investment Management LLC Lowers Stock Holdings in Kymera Therapeutics, Inc. $KYMR

Voya Investment Management LLC reduced its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 36.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,624 shares of the company's stock after selling 22,519 shares during the quarter. Voya Investment Management LLC owned about 0.06% of Kymera Therapeutics worth $1,057,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Siren L.L.C. raised its stake in Kymera Therapeutics by 9.1% in the first quarter. Siren L.L.C. now owns 3,240,313 shares of the company's stock valued at $88,687,000 after purchasing an additional 270,580 shares in the last quarter. Rhumbline Advisers raised its stake in Kymera Therapeutics by 9.0% in the first quarter. Rhumbline Advisers now owns 69,928 shares of the company's stock valued at $1,914,000 after purchasing an additional 5,771 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in Kymera Therapeutics in the fourth quarter valued at approximately $344,000. GAMMA Investing LLC raised its stake in Kymera Therapeutics by 3,851.5% in the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock valued at $183,000 after purchasing an additional 6,509 shares in the last quarter. Finally, Millennium Management LLC raised its stake in Kymera Therapeutics by 205.0% in the fourth quarter. Millennium Management LLC now owns 115,918 shares of the company's stock valued at $4,663,000 after purchasing an additional 77,912 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on KYMR. B. Riley raised shares of Kymera Therapeutics to a "strong-buy" rating and set a $60.00 target price on the stock in a research note on Wednesday, July 30th. Guggenheim reaffirmed a "buy" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, June 3rd. JPMorgan Chase & Co. increased their price target on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the company an "overweight" rating in a research report on Tuesday, June 3rd. Bank of America upgraded shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective for the company in a report on Monday, June 2nd. Finally, HC Wainwright upped their price objective on shares of Kymera Therapeutics from $60.00 to $70.00 and gave the company a "buy" rating in a research note on Thursday, September 18th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Kymera Therapeutics has a consensus rating of "Buy" and an average price target of $59.95.

Kymera Therapeutics Trading Down 0.3%

Shares of Kymera Therapeutics stock opened at $50.87 on Wednesday. The company's fifty day simple moving average is $44.09 and its two-hundred day simple moving average is $38.17. The company has a market cap of $3.64 billion, a P/E ratio of -14.66 and a beta of 2.17. Kymera Therapeutics, Inc. has a 12-month low of $19.44 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). The company had revenue of $11.48 million for the quarter, compared to analysts' expectations of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The firm's revenue for the quarter was down 55.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.58) earnings per share. Analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the transaction, the chief executive officer directly owned 660,482 shares of the company's stock, valued at approximately $32,363,618. The trade was a 4.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bvf Partners L. P/Il bought 317,167 shares of Kymera Therapeutics stock in a transaction dated Monday, June 30th. The stock was acquired at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the completion of the transaction, the director directly owned 2,798,795 shares in the company, valued at approximately $123,146,980. This trade represents a 12.78% increase in their ownership of the stock. The disclosure for this purchase can be found here. 16.01% of the stock is currently owned by company insiders.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.